Paxlovid™ Resources for Pharmacists

British Columbia has funded the oral antiviral drug Paxlovid™ (nirmatrelvir/ritonavir) to treat mild-to-moderate COVID-19 in adults who do not require hospitalization and are at high risk of progressing to serious illness. Select community pharmacies will be able to dispense Paxlovid™

This page is a resource for B.C. community pharmacists for information on Paxlovid™.

Overview

Updated March 23, 2022


The eligibility criteria for Paxlovid™ is available on the BCCDC website. An updated prescription form is also available. 

PharmaCare has stated pharmacists are only following up on 45% of eligible Paxlovid™ dispenses. Pharmacists are required to follow up with the patient and bill in PharmaNet on day 6 to 10 after the date of dispense of Paxlovid™. 

When counselling a patient, inform them that a pharmacist will call them within this timeframe for follow-up and monitor any adverse drug events (ADEs). If the patient cannot be contacted/reached after 3 attempts, please document in the patient’s profile on your local system as usual. 

During the follow-up, record the number of days therapy was completed, and if stopped early, the reason for stopping. Document any ADEs, including the severity and management of each ADE. A temporary $15 PAX-F Clinical Service fee for follow-up can be claimed per Paxlovid™ course. The Association has provided a Paxlovid SIG follow-up claim template pharmacies may use for this purpose. 

PharmaCare states a small number of claims so far have contained errors in the SIG code used to document follow up. The most common omission is a missing ‘Stopped Early/ Reason’ code (i.e. NA – Not stopped early- Adverse Effects). 

  • Example: 888-348-9284_5_ADE1MP should be 888-348-9284_5_NA_ADE1MP indicating the patient did not stop early but did experience ADEs.

For more information on the procedure for follow-up, documentation, and how to enter data in PharmaNet, refer to Dispensing Paxlovid and Monitoring Adverse Drug Events: A Guide for B.C. Community Pharmacists

A reminder that publicly funded Paxlovid™ is available free of charge to eligible patients for the treatment of mild to moderate COVID-19 and to prevent hospitalization. Pharmacies need to order the product directly from their regular distributor in advance. 

Since the drug should be started within 5 days of symptom onset to be effective, participating pharmacies are required to have 1 treatment course in your pharmacy in case you receive a prescription. After you receive the product, prescribers will be able to locate your pharmacy on the list of pharmacies that stock the medication when determining where to fax the prescription. 
 

Other Resources